| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hospitalization | 8 | 2021 | 201 | 2.620 |
Why?
|
| Antipsychotic Agents | 3 | 2022 | 24 | 2.240 |
Why?
|
| Emergency Service, Hospital | 7 | 2020 | 122 | 2.140 |
Why?
|
| Medicaid | 8 | 2022 | 55 | 2.000 |
Why?
|
| United States | 38 | 2026 | 2226 | 2.000 |
Why?
|
| Diabetic Foot | 4 | 2017 | 17 | 1.860 |
Why?
|
| Hepatitis C, Chronic | 4 | 2019 | 32 | 1.790 |
Why?
|
| Cost of Illness | 6 | 2018 | 54 | 1.590 |
Why?
|
| Medication Therapy Management | 4 | 2026 | 20 | 1.550 |
Why?
|
| Schizophrenia | 2 | 2022 | 51 | 1.460 |
Why?
|
| Cross-Sectional Studies | 19 | 2026 | 996 | 1.370 |
Why?
|
| Pericarditis | 2 | 2021 | 14 | 1.330 |
Why?
|
| Health Care Costs | 7 | 2015 | 50 | 1.310 |
Why?
|
| Antiviral Agents | 3 | 2019 | 114 | 1.170 |
Why?
|
| Hepacivirus | 2 | 2019 | 49 | 1.170 |
Why?
|
| Drug Interactions | 9 | 2019 | 79 | 1.120 |
Why?
|
| Retrospective Studies | 27 | 2022 | 2635 | 1.060 |
Why?
|
| Humans | 67 | 2026 | 28896 | 1.050 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 4 | 2026 | 68 | 0.980 |
Why?
|
| Cost-Benefit Analysis | 8 | 2014 | 115 | 0.940 |
Why?
|
| Hospital Charges | 3 | 2015 | 8 | 0.940 |
Why?
|
| Male | 43 | 2026 | 13943 | 0.900 |
Why?
|
| Neoplasms | 4 | 2018 | 874 | 0.890 |
Why?
|
| Personnel Staffing and Scheduling | 2 | 2025 | 44 | 0.890 |
Why?
|
| Middle Aged | 27 | 2019 | 7416 | 0.880 |
Why?
|
| Ambulatory Care | 4 | 2022 | 60 | 0.850 |
Why?
|
| Diabetes Mellitus | 2 | 2018 | 215 | 0.840 |
Why?
|
| Female | 41 | 2026 | 15646 | 0.820 |
Why?
|
| Inpatients | 5 | 2018 | 60 | 0.810 |
Why?
|
| Delivery of Health Care | 3 | 2017 | 118 | 0.790 |
Why?
|
| Psychotic Disorders | 1 | 2022 | 23 | 0.760 |
Why?
|
| Bipolar Disorder | 1 | 2022 | 42 | 0.740 |
Why?
|
| Drug Costs | 3 | 2018 | 17 | 0.730 |
Why?
|
| Length of Stay | 8 | 2021 | 245 | 0.720 |
Why?
|
| Cohort Studies | 9 | 2021 | 897 | 0.690 |
Why?
|
| Adult | 21 | 2022 | 8035 | 0.690 |
Why?
|
| Aged | 18 | 2026 | 5599 | 0.690 |
Why?
|
| Multivariate Analysis | 9 | 2018 | 302 | 0.690 |
Why?
|
| Anti-Bacterial Agents | 6 | 2018 | 536 | 0.660 |
Why?
|
| Nursing Staff, Hospital | 1 | 2020 | 19 | 0.630 |
Why?
|
| Alzheimer Disease | 1 | 2022 | 225 | 0.630 |
Why?
|
| Virus Diseases | 1 | 2020 | 39 | 0.620 |
Why?
|
| Depression | 2 | 2014 | 225 | 0.620 |
Why?
|
| Pharmacists | 5 | 2026 | 74 | 0.610 |
Why?
|
| HIV Infections | 2 | 2018 | 165 | 0.610 |
Why?
|
| Coinfection | 1 | 2018 | 14 | 0.590 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2018 | 22 | 0.590 |
Why?
|
| Comorbidity | 7 | 2019 | 261 | 0.580 |
Why?
|
| Financial Statements | 1 | 2018 | 2 | 0.570 |
Why?
|
| Medication Adherence | 2 | 2018 | 48 | 0.570 |
Why?
|
| Managed Care Programs | 6 | 2015 | 16 | 0.570 |
Why?
|
| Patient Care Management | 1 | 2018 | 10 | 0.570 |
Why?
|
| Hepatitis C | 1 | 2018 | 42 | 0.570 |
Why?
|
| Education, Pharmacy, Graduate | 1 | 2018 | 25 | 0.570 |
Why?
|
| Lung Diseases | 1 | 2018 | 43 | 0.550 |
Why?
|
| Liver Cirrhosis | 1 | 2018 | 78 | 0.530 |
Why?
|
| Health Expenditures | 3 | 2014 | 30 | 0.510 |
Why?
|
| Administration, Oral | 4 | 2022 | 190 | 0.480 |
Why?
|
| Poisoning | 1 | 2015 | 2 | 0.470 |
Why?
|
| Health Status | 2 | 2014 | 149 | 0.470 |
Why?
|
| Acetaminophen | 1 | 2015 | 11 | 0.470 |
Why?
|
| Asthma | 3 | 2008 | 61 | 0.470 |
Why?
|
| Quality-Adjusted Life Years | 3 | 2014 | 18 | 0.470 |
Why?
|
| Hypertension | 1 | 2018 | 309 | 0.460 |
Why?
|
| Healthcare Disparities | 2 | 2019 | 97 | 0.460 |
Why?
|
| Oklahoma | 5 | 2025 | 1053 | 0.460 |
Why?
|
| Aged, 80 and over | 9 | 2026 | 2065 | 0.450 |
Why?
|
| Medication Errors | 4 | 2009 | 26 | 0.440 |
Why?
|
| Sepsis | 1 | 2015 | 86 | 0.440 |
Why?
|
| Community Pharmacy Services | 3 | 2018 | 22 | 0.440 |
Why?
|
| Regression Analysis | 5 | 2012 | 211 | 0.440 |
Why?
|
| Life Expectancy | 1 | 2014 | 23 | 0.430 |
Why?
|
| Patient Outcome Assessment | 1 | 2014 | 14 | 0.430 |
Why?
|
| Sertraline | 3 | 2008 | 5 | 0.420 |
Why?
|
| Treatment Outcome | 11 | 2018 | 2426 | 0.420 |
Why?
|
| Vancomycin | 3 | 2018 | 59 | 0.420 |
Why?
|
| Serotonin Uptake Inhibitors | 3 | 2008 | 26 | 0.420 |
Why?
|
| Vascular Surgical Procedures | 1 | 2014 | 55 | 0.420 |
Why?
|
| Efficiency | 2 | 2013 | 18 | 0.410 |
Why?
|
| Clostridium Infections | 3 | 2018 | 67 | 0.410 |
Why?
|
| Bayes Theorem | 2 | 2019 | 102 | 0.410 |
Why?
|
| Surveys and Questionnaires | 4 | 2014 | 1002 | 0.410 |
Why?
|
| Endovascular Procedures | 1 | 2014 | 74 | 0.400 |
Why?
|
| Educational Measurement | 3 | 2025 | 137 | 0.400 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2013 | 44 | 0.390 |
Why?
|
| Sick Leave | 1 | 2012 | 1 | 0.390 |
Why?
|
| Health Care Sector | 1 | 2012 | 1 | 0.390 |
Why?
|
| Practice Patterns, Physicians' | 5 | 2022 | 167 | 0.390 |
Why?
|
| Hospitals, Veterans | 3 | 2008 | 22 | 0.380 |
Why?
|
| Drug Prescriptions | 5 | 2019 | 46 | 0.380 |
Why?
|
| Curriculum | 3 | 2025 | 304 | 0.370 |
Why?
|
| Risk Factors | 7 | 2018 | 2127 | 0.370 |
Why?
|
| Medical Order Entry Systems | 2 | 2009 | 4 | 0.370 |
Why?
|
| Commerce | 1 | 2012 | 61 | 0.370 |
Why?
|
| Disease Progression | 1 | 2013 | 477 | 0.350 |
Why?
|
| Patient Readmission | 2 | 2022 | 108 | 0.350 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2015 | 344 | 0.350 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 3 | 2008 | 67 | 0.350 |
Why?
|
| Adolescent | 11 | 2019 | 3198 | 0.350 |
Why?
|
| Students, Pharmacy | 2 | 2025 | 91 | 0.340 |
Why?
|
| Socioeconomic Factors | 3 | 2018 | 261 | 0.340 |
Why?
|
| Diphosphonates | 1 | 2010 | 15 | 0.340 |
Why?
|
| Bone Density Conservation Agents | 1 | 2010 | 18 | 0.340 |
Why?
|
| Treatment Failure | 3 | 2019 | 73 | 0.330 |
Why?
|
| Economics, Pharmaceutical | 2 | 2008 | 6 | 0.330 |
Why?
|
| Decision Support Techniques | 4 | 2013 | 51 | 0.330 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2014 | 433 | 0.320 |
Why?
|
| Pharmacy Service, Hospital | 3 | 2008 | 14 | 0.320 |
Why?
|
| Osteoporosis | 1 | 2010 | 63 | 0.320 |
Why?
|
| Health Care Surveys | 5 | 2017 | 67 | 0.310 |
Why?
|
| Adrenal Cortex Hormones | 3 | 2020 | 75 | 0.300 |
Why?
|
| Sustained Virologic Response | 2 | 2019 | 4 | 0.300 |
Why?
|
| Workload | 2 | 2007 | 43 | 0.300 |
Why?
|
| Drug Information Services | 1 | 2009 | 1 | 0.300 |
Why?
|
| Fentanyl | 2 | 2019 | 35 | 0.280 |
Why?
|
| Child | 9 | 2019 | 2292 | 0.280 |
Why?
|
| Child, Preschool | 6 | 2019 | 1174 | 0.270 |
Why?
|
| Longitudinal Studies | 3 | 2018 | 429 | 0.270 |
Why?
|
| Analgesics, Opioid | 2 | 2019 | 121 | 0.260 |
Why?
|
| Critical Illness | 2 | 2017 | 66 | 0.260 |
Why?
|
| Medicare | 2 | 2018 | 126 | 0.250 |
Why?
|
| Mortality | 2 | 2018 | 46 | 0.250 |
Why?
|
| Young Adult | 5 | 2018 | 2839 | 0.250 |
Why?
|
| Telecommunications | 1 | 2006 | 4 | 0.250 |
Why?
|
| Linear Models | 3 | 2015 | 202 | 0.240 |
Why?
|
| Hospital Mortality | 2 | 2018 | 159 | 0.240 |
Why?
|
| Patient Discharge | 2 | 2026 | 109 | 0.240 |
Why?
|
| Home Care Services | 1 | 2026 | 39 | 0.230 |
Why?
|
| Levofloxacin | 1 | 2005 | 3 | 0.230 |
Why?
|
| Ofloxacin | 1 | 2005 | 4 | 0.230 |
Why?
|
| Clarithromycin | 1 | 2005 | 7 | 0.230 |
Why?
|
| Chronic Disease | 3 | 2017 | 274 | 0.230 |
Why?
|
| Erythromycin | 1 | 2005 | 15 | 0.230 |
Why?
|
| Azithromycin | 1 | 2005 | 11 | 0.230 |
Why?
|
| Pneumonia, Bacterial | 1 | 2005 | 18 | 0.220 |
Why?
|
| Acute Disease | 3 | 2020 | 155 | 0.220 |
Why?
|
| Community-Acquired Infections | 1 | 2005 | 31 | 0.220 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2005 | 18 | 0.220 |
Why?
|
| Bone Marrow Transplantation | 1 | 2005 | 49 | 0.220 |
Why?
|
| Amputation | 2 | 2015 | 42 | 0.220 |
Why?
|
| Piperazines | 1 | 2005 | 50 | 0.220 |
Why?
|
| Antineoplastic Agents | 3 | 2010 | 686 | 0.210 |
Why?
|
| Drug Utilization | 2 | 2022 | 28 | 0.210 |
Why?
|
| Accounting | 1 | 2004 | 1 | 0.210 |
Why?
|
| Pyrimidines | 1 | 2005 | 128 | 0.210 |
Why?
|
| Drug Industry | 1 | 2004 | 15 | 0.210 |
Why?
|
| Education, Pharmacy | 2 | 2025 | 124 | 0.210 |
Why?
|
| Hospital Costs | 2 | 2014 | 31 | 0.200 |
Why?
|
| Paliperidone Palmitate | 1 | 2022 | 3 | 0.190 |
Why?
|
| Drug Therapy, Combination | 4 | 2018 | 209 | 0.190 |
Why?
|
| Heart Failure | 1 | 2005 | 253 | 0.190 |
Why?
|
| Injections | 1 | 2022 | 31 | 0.190 |
Why?
|
| Delayed-Action Preparations | 1 | 2022 | 44 | 0.190 |
Why?
|
| Obesity | 2 | 2019 | 701 | 0.190 |
Why?
|
| Outpatients | 1 | 2022 | 44 | 0.190 |
Why?
|
| Hospitals | 1 | 2022 | 77 | 0.180 |
Why?
|
| Multiple Sclerosis | 2 | 2013 | 89 | 0.180 |
Why?
|
| Pericardiectomy | 1 | 2021 | 3 | 0.180 |
Why?
|
| Pericardiocentesis | 1 | 2021 | 4 | 0.180 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 2 | 2020 | 78 | 0.170 |
Why?
|
| Infant | 4 | 2018 | 1026 | 0.160 |
Why?
|
| Pharmacies | 2 | 2012 | 19 | 0.160 |
Why?
|
| Databases as Topic | 3 | 2010 | 22 | 0.160 |
Why?
|
| Chest Pain | 1 | 2020 | 26 | 0.160 |
Why?
|
| Triage | 1 | 2020 | 34 | 0.160 |
Why?
|
| Anesthetics, Intravenous | 2 | 2017 | 15 | 0.150 |
Why?
|
| United States Department of Veterans Affairs | 3 | 2008 | 26 | 0.150 |
Why?
|
| Neonatal Abstinence Syndrome | 1 | 2019 | 10 | 0.150 |
Why?
|
| Time Factors | 3 | 2017 | 1613 | 0.150 |
Why?
|
| Infant, Newborn | 3 | 2019 | 916 | 0.150 |
Why?
|
| Diagnosis-Related Groups | 1 | 2018 | 10 | 0.150 |
Why?
|
| Methadone | 1 | 2019 | 18 | 0.150 |
Why?
|
| Aspirin | 1 | 2020 | 125 | 0.150 |
Why?
|
| Occupations | 1 | 2018 | 9 | 0.150 |
Why?
|
| Genotype | 2 | 2018 | 461 | 0.150 |
Why?
|
| Postoperative Complications | 2 | 2014 | 634 | 0.140 |
Why?
|
| Administrative Claims, Healthcare | 1 | 2018 | 2 | 0.140 |
Why?
|
| Prescription Drug Misuse | 1 | 2018 | 5 | 0.140 |
Why?
|
| Writing | 1 | 2018 | 14 | 0.140 |
Why?
|
| Feedback | 1 | 2018 | 33 | 0.140 |
Why?
|
| Sleep Apnea Syndromes | 1 | 2018 | 32 | 0.140 |
Why?
|
| Coronary Disease | 1 | 2019 | 120 | 0.140 |
Why?
|
| Drug Overdose | 1 | 2018 | 11 | 0.140 |
Why?
|
| Diagnosis, Differential | 1 | 2020 | 379 | 0.140 |
Why?
|
| Prescription Drugs | 1 | 2018 | 15 | 0.140 |
Why?
|
| Retirement | 1 | 2018 | 11 | 0.140 |
Why?
|
| Education | 1 | 2018 | 33 | 0.140 |
Why?
|
| Needs Assessment | 1 | 2018 | 56 | 0.140 |
Why?
|
| Acute Coronary Syndrome | 1 | 2019 | 64 | 0.140 |
Why?
|
| Follow-Up Studies | 2 | 2018 | 1032 | 0.140 |
Why?
|
| Tobramycin | 1 | 2017 | 13 | 0.140 |
Why?
|
| Metronidazole | 1 | 2017 | 16 | 0.140 |
Why?
|
| Pharmaceutical Services | 1 | 2018 | 41 | 0.140 |
Why?
|
| Opioid-Related Disorders | 1 | 2018 | 43 | 0.140 |
Why?
|
| Learning | 1 | 2018 | 100 | 0.130 |
Why?
|
| Logistic Models | 2 | 2018 | 410 | 0.130 |
Why?
|
| Patient Compliance | 2 | 2008 | 76 | 0.130 |
Why?
|
| Heart Defects, Congenital | 1 | 2018 | 95 | 0.130 |
Why?
|
| Hypnotics and Sedatives | 1 | 2017 | 29 | 0.130 |
Why?
|
| Citalopram | 2 | 2007 | 7 | 0.130 |
Why?
|
| Antidepressive Agents | 2 | 2007 | 29 | 0.130 |
Why?
|
| Medical Errors | 1 | 2016 | 9 | 0.130 |
Why?
|
| Odds Ratio | 2 | 2014 | 237 | 0.130 |
Why?
|
| Anti-HIV Agents | 1 | 2016 | 20 | 0.130 |
Why?
|
| Survival Analysis | 2 | 2015 | 288 | 0.130 |
Why?
|
| Depressive Disorder | 2 | 2007 | 56 | 0.120 |
Why?
|
| Patient Transfer | 1 | 2016 | 43 | 0.120 |
Why?
|
| Incidence | 2 | 2015 | 572 | 0.120 |
Why?
|
| State Health Plans | 1 | 2015 | 3 | 0.120 |
Why?
|
| Fee-for-Service Plans | 1 | 2015 | 8 | 0.120 |
Why?
|
| Adjuvants, Immunologic | 2 | 2013 | 68 | 0.120 |
Why?
|
| Skin Diseases, Bacterial | 1 | 2015 | 9 | 0.120 |
Why?
|
| Soft Tissue Infections | 1 | 2015 | 10 | 0.120 |
Why?
|
| Costs and Cost Analysis | 3 | 2015 | 40 | 0.110 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2008 | 303 | 0.110 |
Why?
|
| Risk | 2 | 2012 | 138 | 0.110 |
Why?
|
| Mediterranean Region | 1 | 2014 | 2 | 0.110 |
Why?
|
| Risk Assessment | 4 | 2019 | 631 | 0.110 |
Why?
|
| Developed Countries | 1 | 2014 | 7 | 0.110 |
Why?
|
| Limb Salvage | 1 | 2014 | 21 | 0.110 |
Why?
|
| Injections, Intravenous | 2 | 2012 | 66 | 0.110 |
Why?
|
| Patient Admission | 1 | 2014 | 30 | 0.110 |
Why?
|
| Developing Countries | 1 | 2014 | 49 | 0.110 |
Why?
|
| Scorpion Venoms | 1 | 2013 | 2 | 0.100 |
Why?
|
| Antivenins | 1 | 2013 | 9 | 0.100 |
Why?
|
| Marketing | 1 | 2013 | 36 | 0.100 |
Why?
|
| Models, Theoretical | 1 | 2014 | 134 | 0.100 |
Why?
|
| Recurrence | 3 | 2018 | 326 | 0.100 |
Why?
|
| Analgesia, Epidural | 1 | 2012 | 4 | 0.100 |
Why?
|
| Deferoxamine | 1 | 2012 | 3 | 0.100 |
Why?
|
| Iron Chelating Agents | 1 | 2012 | 2 | 0.100 |
Why?
|
| Interferon-beta | 1 | 2013 | 40 | 0.100 |
Why?
|
| Triazoles | 1 | 2012 | 16 | 0.100 |
Why?
|
| Benzoates | 1 | 2012 | 30 | 0.090 |
Why?
|
| Pancreaticoduodenectomy | 1 | 2012 | 42 | 0.090 |
Why?
|
| Conscious Sedation | 1 | 2012 | 10 | 0.090 |
Why?
|
| Postoperative Care | 1 | 2012 | 68 | 0.090 |
Why?
|
| Emergencies | 1 | 2012 | 28 | 0.090 |
Why?
|
| Propofol | 1 | 2012 | 10 | 0.090 |
Why?
|
| Ovarian Neoplasms | 2 | 2010 | 607 | 0.090 |
Why?
|
| Anemia, Sickle Cell | 1 | 2012 | 39 | 0.090 |
Why?
|
| Drug Therapy, Computer-Assisted | 2 | 2009 | 4 | 0.090 |
Why?
|
| Data Collection | 3 | 2008 | 106 | 0.090 |
Why?
|
| Monte Carlo Method | 3 | 2008 | 62 | 0.090 |
Why?
|
| Reproducibility of Results | 1 | 2014 | 787 | 0.090 |
Why?
|
| Etidronic Acid | 1 | 2010 | 1 | 0.080 |
Why?
|
| Osteitis | 1 | 2010 | 2 | 0.080 |
Why?
|
| Jaw Diseases | 1 | 2010 | 4 | 0.080 |
Why?
|
| Alendronate | 1 | 2010 | 6 | 0.080 |
Why?
|
| Oral Surgical Procedures | 1 | 2010 | 6 | 0.080 |
Why?
|
| Osteomyelitis | 1 | 2010 | 14 | 0.080 |
Why?
|
| Imidazoles | 1 | 2010 | 63 | 0.080 |
Why?
|
| Multiple Myeloma | 1 | 2010 | 39 | 0.080 |
Why?
|
| Insurance, Health, Reimbursement | 2 | 2013 | 10 | 0.080 |
Why?
|
| Databases, Factual | 3 | 2018 | 270 | 0.080 |
Why?
|
| Quality of Life | 1 | 2014 | 521 | 0.080 |
Why?
|
| Neoplasms, Glandular and Epithelial | 1 | 2010 | 72 | 0.080 |
Why?
|
| Electronic Prescribing | 1 | 2009 | 2 | 0.070 |
Why?
|
| Prevalence | 1 | 2010 | 518 | 0.070 |
Why?
|
| Markov Chains | 2 | 2007 | 16 | 0.070 |
Why?
|
| Outpatient Clinics, Hospital | 1 | 2008 | 7 | 0.070 |
Why?
|
| Medical Oncology | 1 | 2010 | 98 | 0.070 |
Why?
|
| Urokinase-Type Plasminogen Activator | 1 | 2008 | 11 | 0.070 |
Why?
|
| Tissue Plasminogen Activator | 1 | 2008 | 36 | 0.070 |
Why?
|
| Albuterol | 1 | 2008 | 4 | 0.070 |
Why?
|
| Adrenergic beta-Agonists | 1 | 2008 | 20 | 0.070 |
Why?
|
| Bronchodilator Agents | 1 | 2008 | 15 | 0.070 |
Why?
|
| Peripheral Vascular Diseases | 1 | 2008 | 64 | 0.070 |
Why?
|
| Adverse Drug Reaction Reporting Systems | 1 | 2007 | 14 | 0.070 |
Why?
|
| Ribavirin | 1 | 2007 | 9 | 0.070 |
Why?
|
| Prostatic Neoplasms | 1 | 2010 | 302 | 0.070 |
Why?
|
| Interferon-alpha | 1 | 2007 | 50 | 0.060 |
Why?
|
| Program Development | 1 | 2007 | 87 | 0.060 |
Why?
|
| Confidence Intervals | 1 | 2007 | 69 | 0.060 |
Why?
|
| Neoadjuvant Therapy | 1 | 2007 | 80 | 0.060 |
Why?
|
| Antihypertensive Agents | 1 | 2007 | 56 | 0.060 |
Why?
|
| Lung Neoplasms | 1 | 2010 | 360 | 0.060 |
Why?
|
| Carcinoma | 1 | 2007 | 74 | 0.060 |
Why?
|
| Polyethylene Glycols | 1 | 2007 | 101 | 0.060 |
Why?
|
| Health Education | 1 | 2007 | 75 | 0.060 |
Why?
|
| Program Evaluation | 1 | 2007 | 174 | 0.060 |
Why?
|
| Severity of Illness Index | 3 | 2018 | 466 | 0.060 |
Why?
|
| Attitude to Computers | 1 | 2006 | 7 | 0.060 |
Why?
|
| Urbanization | 1 | 2006 | 8 | 0.060 |
Why?
|
| Cisplatin | 1 | 2007 | 186 | 0.060 |
Why?
|
| Automation | 1 | 2006 | 21 | 0.060 |
Why?
|
| Drug Utilization Review | 1 | 2005 | 7 | 0.060 |
Why?
|
| Sodium Potassium Chloride Symporter Inhibitors | 1 | 2005 | 4 | 0.060 |
Why?
|
| Digoxin | 1 | 2005 | 8 | 0.060 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2005 | 32 | 0.060 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2005 | 66 | 0.060 |
Why?
|
| Clinical Competence | 1 | 2007 | 239 | 0.060 |
Why?
|
| Models, Econometric | 1 | 2005 | 5 | 0.060 |
Why?
|
| Imatinib Mesylate | 1 | 2005 | 15 | 0.060 |
Why?
|
| Breast Neoplasms | 1 | 2010 | 483 | 0.060 |
Why?
|
| Benzamides | 1 | 2005 | 39 | 0.060 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2019 | 612 | 0.050 |
Why?
|
| Biomedical Research | 1 | 2005 | 98 | 0.050 |
Why?
|
| Diarrhea | 2 | 2017 | 57 | 0.050 |
Why?
|
| Practice Guidelines as Topic | 1 | 2004 | 245 | 0.050 |
Why?
|
| Insurance Claim Review | 2 | 2012 | 11 | 0.040 |
Why?
|
| Metabolic Clearance Rate | 1 | 2019 | 18 | 0.040 |
Why?
|
| Proportional Hazards Models | 2 | 2012 | 226 | 0.040 |
Why?
|
| Academic Medical Centers | 1 | 2019 | 76 | 0.040 |
Why?
|
| Sex Factors | 2 | 2012 | 469 | 0.040 |
Why?
|
| Propensity Score | 1 | 2018 | 59 | 0.040 |
Why?
|
| Computer Simulation | 1 | 2019 | 238 | 0.040 |
Why?
|
| Nurse Practitioners | 2 | 2008 | 8 | 0.040 |
Why?
|
| Disease Management | 1 | 2018 | 91 | 0.030 |
Why?
|
| Leukocyte Count | 1 | 2017 | 25 | 0.030 |
Why?
|
| Age Factors | 2 | 2012 | 737 | 0.030 |
Why?
|
| Administration, Inhalation | 1 | 2017 | 36 | 0.030 |
Why?
|
| Body Mass Index | 1 | 2019 | 412 | 0.030 |
Why?
|
| Insurance, Pharmaceutical Services | 2 | 2008 | 9 | 0.030 |
Why?
|
| Drug Monitoring | 1 | 2017 | 36 | 0.030 |
Why?
|
| Cystic Fibrosis | 1 | 2017 | 34 | 0.030 |
Why?
|
| Physicians | 2 | 2008 | 83 | 0.030 |
Why?
|
| Infusions, Intravenous | 1 | 2017 | 102 | 0.030 |
Why?
|
| Acute Kidney Injury | 1 | 2017 | 74 | 0.030 |
Why?
|
| Registries | 1 | 2019 | 397 | 0.030 |
Why?
|
| Hospitals, Teaching | 1 | 2016 | 26 | 0.030 |
Why?
|
| African Americans | 1 | 2019 | 352 | 0.030 |
Why?
|
| Neutrophils | 1 | 2017 | 185 | 0.030 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2007 | 409 | 0.030 |
Why?
|
| Drug Administration Schedule | 1 | 2015 | 224 | 0.030 |
Why?
|
| Pregnancy | 1 | 2019 | 1259 | 0.030 |
Why?
|
| Patient Selection | 1 | 2015 | 150 | 0.030 |
Why?
|
| Health Services Accessibility | 1 | 2015 | 121 | 0.030 |
Why?
|
| Interferon beta-1a | 1 | 2013 | 4 | 0.020 |
Why?
|
| Absenteeism | 1 | 2013 | 7 | 0.020 |
Why?
|
| Injections, Intramuscular | 1 | 2013 | 22 | 0.020 |
Why?
|
| Respiratory Insufficiency | 1 | 2012 | 14 | 0.020 |
Why?
|
| Patient Preference | 1 | 2012 | 34 | 0.020 |
Why?
|
| Hypotension | 1 | 2012 | 20 | 0.020 |
Why?
|
| Pain, Postoperative | 1 | 2012 | 62 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2012 | 194 | 0.020 |
Why?
|
| Blood Transfusion | 1 | 2012 | 77 | 0.020 |
Why?
|
| Game Theory | 1 | 2010 | 1 | 0.020 |
Why?
|
| Interviews as Topic | 1 | 2010 | 162 | 0.020 |
Why?
|
| Neoplasm Staging | 1 | 2010 | 480 | 0.020 |
Why?
|
| Physician Assistants | 1 | 2008 | 14 | 0.020 |
Why?
|
| Salmeterol Xinafoate | 1 | 2008 | 1 | 0.020 |
Why?
|
| Arizona | 1 | 2008 | 38 | 0.020 |
Why?
|
| Medical Records Systems, Computerized | 1 | 2008 | 21 | 0.020 |
Why?
|
| Observation | 1 | 2007 | 5 | 0.020 |
Why?
|
| Data Interpretation, Statistical | 1 | 2008 | 58 | 0.020 |
Why?
|
| Models, Economic | 1 | 2007 | 8 | 0.020 |
Why?
|
| Clinical Pharmacy Information Systems | 1 | 2007 | 5 | 0.020 |
Why?
|
| Ambulatory Care Facilities | 1 | 2007 | 54 | 0.020 |
Why?
|
| Infusions, Parenteral | 1 | 2007 | 37 | 0.020 |
Why?
|
| Safety Management | 1 | 2007 | 13 | 0.020 |
Why?
|
| Office Visits | 1 | 2007 | 8 | 0.020 |
Why?
|
| Nausea | 1 | 2007 | 17 | 0.020 |
Why?
|
| Erectile Dysfunction | 1 | 2007 | 15 | 0.020 |
Why?
|
| Thyroid Hormones | 1 | 2007 | 37 | 0.020 |
Why?
|
| Medical Audit | 1 | 2007 | 15 | 0.020 |
Why?
|
| Headache | 1 | 2007 | 34 | 0.020 |
Why?
|
| Pharmaceutical Preparations | 1 | 2007 | 49 | 0.020 |
Why?
|
| Guideline Adherence | 1 | 2007 | 95 | 0.020 |
Why?
|
| Sleep Initiation and Maintenance Disorders | 1 | 2007 | 24 | 0.020 |
Why?
|
| Fibrosis | 1 | 2007 | 143 | 0.020 |
Why?
|
| Attitude of Health Personnel | 1 | 2007 | 150 | 0.020 |
Why?
|
| Recombinant Proteins | 1 | 2007 | 416 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2008 | 739 | 0.010 |
Why?
|
| Double-Blind Method | 1 | 2007 | 422 | 0.010 |
Why?
|
| Research Design | 1 | 2007 | 187 | 0.010 |
Why?
|
| Anticoagulants | 1 | 2007 | 297 | 0.010 |
Why?
|
| Algorithms | 1 | 2007 | 431 | 0.010 |
Why?
|
| Liver | 1 | 2007 | 471 | 0.010 |
Why?
|